31
Mar

SR One, GlaxoSmithKline’s venture arm, has joined a syndicate backing a big midstage study of a new kidney drug developed by Montreal-based Thrasos Therapeutics.

…read more

Source: GlaxoSmithKline leads a $21M round for PhII kidney drug developer Thrasos

    

0 No comments